TECA hybrid artificial liver support system in treatment of acute liver failure

Table 1 Clinical data of six patients with liver failure

No	M/F	Age	Diagnosis	General condition	Program of treatment	t (treatment)/h
1	M	50	Liver cir rhosis (decomp ensation) HCC, ALF	Hepatic encephalopathylethargy	Whole blood CA &TECA-BALSS	2.5
2	F	50	Post operation of cancerof biliary duct, ALF, ARF	Hepatic encephalopathylethargy	Plasma CA &TECA-BALSS	2+4
3	M	32	Hepatitis BLiver failure	Hepatic encephalopathy	Plasma CA &TECA-BALSS	2+4
4	F	43	Acute viral hepatiti sfulminant hepatic failure	Hepatic encephalopathy (stage IV)	PE and TECA-BALSS	2+4
5	M	32	Hepatitis B (decompens ation) Liver failure	Hepatic encephalopathy (stage IV)	PE and TECA-BALSS	2+5
6	F	34	Drug induced hepaticinjury, liver failure	Hepatic encephalopathy lethargy	PE and TECA-BALSS	2+5

Table 2 Changes of pre- and post-treatment by TECA-HALSS in case 2

Parameters	Pre-HALSS	Post CA	4 h post-BALSS	2d post-HALSS
NH3 (μg/L)	134	93	30	53
ALT (IU/L)	64	27	29	53
AST (IU/L)	69	47	269	97
TB (μmol/L)	495	423	400	405
DB (μmol/L)	240	204	198	350
UN (mmol/L)	41	35.7	36.6	37
Cr (μmol/L)	651	121	407
K+ (mmol/L)	4.99	4.66	4.47	4.9
Na+ (mmol/L)	132	131	133	131
Cl- (mmol/L)	99.6	104	104	96
Mentality	Lethargy	Lethargy	Consciousness	Consciousness

Table 3 Changes pre- and post-treatment by TECA-HALSS in case 4

Pre-HALSS		HALSS			Post-HALSS
		Post-PE	BALSS 2 h	BALSS 4 h	d1	d2	d4	d7
NH3 (μg/L)	78	114	101	108
ALT (IU/L)	1352	408	390	336			225	146
AST (IU/L)	142	45	629	751			45	63
TB (μmol/L)	17.11	7.23	9.99	9.22			16.95	29.18
DB (μmol/L)	12.03	5.08	6.25	5.72			12.74	21.26
TP (g/L)	69.8	54.5	48.1	43.5			48	56.2
ALB (g/L)	34.29	31.8	28.5	25.6			23.3	24.6
ALP (IU/L)	297	144	140	115			176	213
PTA (%)	13.15				21.6	29.6		48.8
Mentality	Deep coma	Deep coma	Deep coma	Deep coma	Superficial coma	Consciousness